Abstract:The selective removal of dysfunctional mitochondria, a process termed mitophagy, is critical for cellular health and impairments have been linked to aging, Parkinson disease, and other neurodegenerative conditions. A central mitophagy pathway is orchestrated by the ubiquitin (Ub) kinase PINK1 together with the E3 Ub ligase PRKN/Parkin. The decoration of damaged mitochondrial domains with phosphorylated Ub (p-S65-Ub) mediates their elimination though the autophagy system. As such p-S65-Ub has emerged as a highly specific and quantitative marker of mitochondrial damage with significant disease relevance. Existing p-S65-Ub antibodies have been successfully employed as research tools in a range of applications including western blot, immunocytochemistry, immunohistochemistry, and enzyme-linked immunosorbent assay. However, physiological levels of p-S65-Ub in the absence of exogenous stress are very low, therefore difficult to detect and require reliable and ultrasensitive methods. Here we generated and characterized a collection of novel recombinant, rabbit monoclonal p-S65-Ub antibodies with high specificity and affinity in certain applications that allow the field to better understand the molecular mechanisms and disease relevance of PINK1-PRKN signaling. These antibodies may also serve as novel diagnostic or prognostic tools to monitor mitochondrial damage in various clinical and pathological specimens. Abbreviations : AD: Alzheimer disease; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; ELISA: enzyme-linked immunosorbent assay; HEK293E cell: human embryonic kidney E cell; ICC: immunocytochemistry; IHC: immunohistochemistry: KO: knockout; LoB: limit of blank; LoD: limit of detection; LoQ: limit of quantification; MEF: mouse embryonic fibroblast; MSD: Meso Scale Discovery; n.s.: non-significant; nonTg: non-transgenic; PBMC: peripheral blood mononuclear cell; PD: Parkinson disease; p-S65-PRKN: phosphorylated PRKN at serine 65; p-S65-Ub: phosphorylated Ub at serine 65; Ub: ubiquitin; WT: wild-type.

Application of Phosphorylation Site-Specific Antibodies to Measure Nuclear Receptor Signaling: Characterization of Novel Phosphoantibodies for Estrogen Receptor α

Characterization of a nanobody-epitope tag interaction and its application for receptor engineering

Epigenetic factors that control estrogen receptor alpha (ERα) binding site utilization and specificity in the MCF-7 human breast cancer cell line

Advances in the Regulation of Nuclear Receptor Function Mediated by the Phosphorylation Pathway

Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)

Determination of Site-Specific Phosphorylation Ratios in Proteins with Targeted Mass Spectrometry

Estrogen Signals through ERβ in Breast Cancer; What We Have Learned since the Discovery of the Receptor

Targeted proteomics analyses of phosphorylation-dependent signalling networks

Developing tyrosine phosphoproteome libraries and dual quantification using a hybrid DIA approach

A Simple Method for the Preparation of Positive Samples to Preliminarily Determine the Quality of Phosphorylation-Specific Antibody

Development and Characterization of Recombinant ADP-Ribose Binding Reagents that Allow Simultaneous Detection of Mono and Poly ADP-Ribose

Development and characterization of phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling in cells and tissue

Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily

Engineered FHA domains can bind to a variety of Phosphothreonine-containing peptides

Phosphoproteomics: a valuable tool for uncovering molecular signaling in cancer cells

Molecularly Imprinted and Cladded Nanotags Enable Specific SERS Bioimaging of Tyrosine Phosphorylation.

A reverse phase protein array based phospho-antibody characterization approach and its applicability for clinical derived tissue specimens

Comprehensive and Reliable Phosphorylation Site Mapping of Individual Phosphoproteins by Combination of Multiple Stage Mass Spectrometric Analysis with a Target-Decoy Database Search.

Molecularly Imprinted and Cladded Nanoparticles Provide Better Phosphorylation Recognition

Recent Advances in Peptidomimetics Antagonists Targeting Estrogen Receptor Α-Coactivator Interaction in Cancer Therapy